ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / STLN / forecast
AHCO (33) SBC (72) SRTA (34) OMDA (53) ⌘ Pro Terminal →

Starling Oncology Inc. (STLN) 12-Month Stock Forecast & Price Target Cone

$6.25 -4.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.19

Starling Oncology Inc. (STLN) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $665.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STLN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Starling Oncology Inc. (NASDAQ: STLN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.25 (-4.29% 1D, market cap $665.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STLN ranks #505 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STLN compare to AHCO and SBC in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), STLN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AHCO (AdaptHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC 2.2%, cap $792.2M) and SBC (SBC Medical Group Holdings Incorporated) posts a B grade (72/100 RQD, P/E 11.5x, ROIC 63.1%, cap $542.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STLN?
▼

Per STLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799191), Starling Oncology Inc. generated $502.7M in revenue (+27.8% YoY), $60.61B in net income, and -$27.8M in free cash flow against $164.7M in total assets and $77.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.19 (-0.96%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (5)Whales (13)SEC (9)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$7 Bull$6 Base$4 Bear
📬 FREE STLN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STLN)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY STLN SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)

20D Institutional Volume Accumulation (±11.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (24% of score)

Altman Z-Score 2.58 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$6.70-1% Next Q
Q2 (-2Q)
43
Grade D$6.63-0.6% Next Q
Q3 (-1Q)
41
Grade D$6.59-5.2% Next Q
Current
38
Grade D-$6.25-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STLN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STLN currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.48) and Max Pain ($6.56) forces dealer call-delta covering toward $7.49.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STLN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your STLN Position Size: $10,000

Shares at $6.25: 1600.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $4.44
$7,104
$-2,896 (-29.0%)
12M Consensus BaseTarget $5.69
$9,104
$-896 (-9.0%)
12M Bull Case BreakoutTarget $7.49
$11,984
+$1,984 (+19.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$674%A
Goldman SachsSector Coverage LeadUNDERPERFORM$769%B
JP MorganUS Large-Cap ResearchSELL$558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STLN)

  • ✓Walkthrough of STLN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
STLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.19%🛡️ HOLDING TREND SUPPORT
2026-11-03O $6.65H $6.65L $6.25C $6.25VOL 1.42M
RES: $7.22SUP: $6.26SMA50: $6.48SMA200: $4.73
$7.41$6.26$5.12$3.97$2.82RES $7.22SUP $6.26$6.252026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STLN Butterfly Map → + Track STLN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +27.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on STLN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STLN)

Health Care Rank #505 of 1015 ⚔️ AHCO vs STLN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STLN vs. AHCO, SBC, SRTA, OMDA)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Starling Oncology Inc. (STLN) ranks #505 by composite RQD confidence (38/100, grade D-) and #400 by equity capitalization ($665.5M). Within this direct 5-issuer industry benchmark cohort, SRTA leads on earnings valuation at 10.2x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with STLN at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
STLN ACTIVE
Starling Oncology Inc.
D- 38/100 — — -35.0% -4.29% $665.5M Benchmark Subject
AHCO
AdaptHealth Corp.
E 33/100 — 18.8% 2.2% +1.72% $792.2M /ahco-vs-stln →
SBC
SBC Medical Group Holdings Incorporated
B 72/100 11.5x 73.3% 63.1% +0.66% $542.5M /sbc-vs-stln →
SRTA
Strata Critical Medical Inc. (Class A)
E 34/100 10.2x 20.9% -7.1% -3.60% $392.8M /srta-vs-stln →
OMDA
Omada Health Inc.
D+ 53/100 — 65.7% -15.7% -4.70% $1.15B /omda-vs-stln →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799191 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Starling Oncology Inc. (STLN) reported GAAP revenue of $502.7M (+27.8% vs. FY2024 revenue of $393.4M , and +55.0% cumulative change since FY2023) , GAAP net income of $60.61B, operating cash flow of -$24.6M, and free cash flow of -$27.8M (+8.4% YoY). On the balance sheet, STLN closed FY2025 with $164.7M in total assets against $77.4M in total debt (Altman Z-Score: 2.58, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $502.7M $60.61B -$24.6M -$27.8M $164.7M $77.4M
FY2024 (FY) 2024-12-31 $393.4M $64.66B -$26.5M -$30.3M $172.7M $93.1M
FY2023 (FY) 2023-12-31 $324.2M -$83.1M -$36.3M -$36.3M — —

3. STLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Starling Oncology Inc. (NASDAQ: STLN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $6.25 (-4.29% 1D, market cap $665.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STLN ranks #505 in composite RQD confidence.

How does STLN compare to AHCO and SBC in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), STLN carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AHCO (AdaptHealth Corp.) holds a E grade (33/100 RQD, P/E N/A, ROIC 2.2%, cap $792.2M) and SBC (SBC Medical Group Holdings Incorporated) posts a B grade (72/100 RQD, P/E 11.5x, ROIC 63.1%, cap $542.5M). Among the 5-stock peer group, SRTA leads on earnings multiple (10.2x) while SBC leads on capital efficiency (63.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for STLN?

Per STLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799191), Starling Oncology Inc. generated $502.7M in revenue (+27.8% YoY), $60.61B in net income, and -$27.8M in free cash flow against $164.7M in total assets and $77.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is STLN trading relative to its 50-day, 200-day, and 52-week technical levels?

STLN last traded at $6.25 (-4.29% on volume of 1,461,255 shares), positioning the stock -3.55% below its 50-day simple moving average ($6.48) and +32.14% above its 200-day simple moving average ($4.73). Across its 52-week range of $2.32 to $7.13, STLN sits at the 81.7% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($5.51 to $6.99).

Direct Sub-Reports: STLN RQD Cockpit STLN 12M Forecast STLN Earnings & Move STLN Dividends & DRIP STLN Insiders & 13F STLN Whale Options STLN Profit Sankey STLN News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

STLN — Starling Oncology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Starling Oncology Inc. (STLN) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.25 (-4.29% 1D, market capitalization $665.5M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -7.2%, and free cash flow yield of -4.10%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.58, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Starling Oncology Inc. (STLN) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Nursing Services industry. It carries a market capitalization of $0.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Starling Oncology Inc. (STLN) reported $502.7M in annual revenue (up from $393.4M in FY2024, +27.8% YoY) and $60.61B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($324.2M revenue, -$83.1M net income) through FY2025, STLN scaled operating cash flow to -$24.6M and free cash flow to -$27.8M, backed by $164.7M in total assets against $77.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -4.10% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $2.32 – $7.13 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector and industry classification (Health Care; Medical/Nursing Services) is the only structural context provided.

  • Key Question #1: Can STLN sustain or expand its -7.2% operating margin and -35.0% ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $502.7M and free cash flow of -$27.8M, how will capital allocation balance growth reinvestment against $77.4M in total debt?
  • Key Question #3: How sensitive is STLN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

STLN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Starling Oncology Inc. (STLN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STLN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STLN Bull vs. Bear Conversation Board — What's Your Call at $6.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STLN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on STLN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $7.77 (+19.0%)
📌 Pinned Debate

Revenue grew from $324.2M in FY 2023 to $502.7M in FY 2025 while institutional flow scored 13/20 in the RQD framework.

Don't sleep on STLN's setup in Health Care. Revenue grew from $324.2M in FY 2023 to $502.7M in FY 2025 while institutional flow scored 13/20 in the RQD framework.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (38/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@RedlineAuditor Shorting a 13/20 institutional whale-flow stock at $6.53 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.90 (-25.0%)
Spot @ $6.53

ROIC of -35% and FCF yield of -4.1% leave the fundamental cash engine scoring 5/20 with operating income negative in every reported per

Sitting on the sidelines or leaning short STLN above $6.53. ROIC of -35% and FCF yield of -4.1% leave the fundamental cash engine scoring 5/20 with operating income negative in every reported period.. Until Fundamental Cash Engine (5/20) and FCF yield (-4.1%) inflect higher, upside is capped near $7.13.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%